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ABSTRACT
Introduction: Dexmedetomidine (Dex) has
sedative, analgesic, and anesthetic-sparing
effects. This meta-analysis examines
demonstrated intraoperative and postoperative
effects of intraoperative Dex administration
during pediatric surgery.
Methods: A search for randomized
placebo-controlled trials was conducted to
identify clinical trials examining intraoperative
Dex use in children, infants, and neonates.
Primary outcome was postoperative opioid
consumption; secondary outcomes were:
postoperative pain intensity and postoperative
nausea and vomiting (PONV).
Results: Fourteen randomized controlled trials
performed during painful procedures were
analyzed. Intraoperative Dex administration
was associated with significantly reduced
postoperative opioid consumption in the
postanesthesia care unit [PACU; risk ratio
(RR) = 0.31 (0.17, 0.59), I2 = 76%, p\0.0001
and cumulative z score using trial sequential
analysis], decreased pain intensity in PACU
[standardized mean difference (SMD) = -1.18
(-1.88, -0.48), I2 = 91%, p\0.0001] but had
no effect upon PONV incidence [RR = 0.67
(0.41, 1.08), I2 = 0%, p = 0.48]. Subgroup
analyses found administering Dex during
adenotonsillectomy and using a bolus\0.5 lg/
kg (irrespective to the use of a continuous
administration) without effects on studies
outcomes. Heterogeneity was high among
results and a high suspicion of publication bias
was present for all analyzed outcomes.
Conclusions: This meta-analysis shows that
intraoperative Dex administration in children
reduces postoperative opioids consumption and
postoperative pain in PACU. According to our
results, optimal bolus dose was found to be
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C0.5 lg/kg. Future studies have to explore this
particular point and the postoperative analgesic





Dexmedetomidine (Dex) is a short-acting
a2-adrenoceptor agonist commonly used in
adult anesthesia and intensive care [1–3]. It
provides analgesia, preserves the ability to be
roused, and avoids respiratory depression [3].
Several studies suggest that Dex can be useful in
specific anesthetic situations. One recent
meta-analysis performed in adults
demonstrated that intraoperative Dex reduced
intraoperative opioid consumption, pain
intensity during PACU stay, opioid
consumption during postanesthesia care unit
(PACU) or intensive care unit (ICU) stay, and
postoperative nausea and vomiting (PONV)
incidence during PACU stay [4]. These
properties, especially the postoperative effects
on analgesia, opioid consumption, and PONV
occurrence, are very interesting while they
might help in promoting rapid rehabilitation
after surgery.
In pediatric populations, numerous studies
of intraoperative Dex use have also been
performed [2]. However, most are
non-randomized trials, small cohorts, or case
reports, which complicate making any
confident conclusions regarding the effects of
intraoperative Dex. In 2013, a meta-analysis in
children found Dex [5] to produce the same
effects as those observed in adults [5] and in the
two last years, two meta-analyses [6, 7] found
this compound to strongly prevent emergence
agitation. However, the potential of Dex to
decrease postoperative pain and provide an
opioid-sparing effect remains debated.
The aim of the present study was to perform
a systematic review and meta-analysis, updating
the previous one published in 2013, and
exploring the postoperative effects of Dex on
postoperative analgesia quality, opioid
consumption, and PONV occurrence.
METHODS
This meta-analysis is based on previously
conducted studies and does not involve any
new studies of human or animal subjects
performed by any of the authors.
Bibliographic Search and Analysis
We conducted this meta-analysis according to
the guidelines of the Cochrane Handbook for
Systematic Reviews [8] of intervention and the
PRISMA statements [9]. Literature databases
included PubMed, EMBASE, Cochrane central
register of controlled trials, clinical trials
register, and open-access journals not indexed
in major databases (Directory of Open Access
Journals, Open Journal of Anesthesiology,
Anesthesiology Research and Practice, Journal
of Anesthesia and Clinical Research, Journal of
Anesthesiology and Clinical Science, Journal of
Anesthesiology and Critical Care Medicine).
The following queries were used to discard
irrelevant results related to postoperative Dex
use: ‘‘Dexmedetomidine’’ and ‘‘children or child
or infant or infants’’. No language restriction
was applied for searches. In addition, a manual
search of the references found in all selected
articles was performed, including reviews and
meta-analyses. Identified articles were
independently assessed by four
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anesthesiologists (Myriam Bellon, Alix Le bot,
Daphne´e Michelet, Julie Hilly) and only those
which fulfilled the following criteria were
included: randomized-controlled, double-blind
studies, patients with neurological and/or
psychiatric diseases excluded, standardized
protocols for anesthesia, analgesia and rescue
analgesics, presence of a control group (placebo
with no active anesthetic or analgesic agent)
and of at least one outcome in relation to:
postoperative analgesia or opioid consumption.
Given the potential impact of neurosurgery on
postoperative neurological function and the
preoperative alteration of those functions in
congenital heart diseases, both cardiac surgery
and neurosurgery were excluded from the area
of this meta-analysis. Abstracts presented at
meetings were not included. The most recent
search was performed in December 2015.
Each reader evaluated the potential presence
of bias and study quality based on the following
criteria: randomization and allocation
concealment (clear, sufficiently detailed
description of methodology demonstrating
whether intervention allocations could have
been foreseen before or during enrolment),
double blinding, incomplete data report
statements (concerning excluded patients and
data) and selective reporting (presence of
studied outcomes report verified). For the
studies meeting these criteria, data were then
independently collated by two anesthesiologists
and included: patient American
Anesthesiologists Association (ASA) physical
status and age, type of surgery, sedative
anesthetic premedication (dose, timing, and
route of administration), Dex administration
characteristics (doses and timing, bolus and
infusion), other hypnotic agents used,
intraoperative analgesia administration (both
systemic or regional analgesia), postoperative
analgesic administered and endpoints of each
study. The primary endpoint of the study was
the opioid-sparing effect of intraoperative Dex
(either expressed as continuous data or as
percentage of patients receiving opioids).
Secondary endpoints were: the quality of
postoperative [either the intensity of
postoperative pain or the presence of a
significant pain defined as: FLACC (Face, Legs,
Activity, Cry, Consolability) [3, visual or
numerical pain scale [3, facial pain scale [3,
and Objective Pain Scale (OPS)[3] [10–13] and
the occurrence of PONV (either both or the
presence of vomiting). Other outcomes such as
emergence agitation and hemodynamic effects
of Dex were not analyzed because of the
restrictive search on studies with postoperative
analgesia outcomes. When conflicting results
were found, the article was rechecked twice by
the two anesthesiologists until a consensus was
found.
Statistical Analysis
Statistical analyses were performed using
Review Manager 5 software (RevMan 5.3, The
Cochrane Collaboration, Oxford, UK) and the
Trial Sequential Analysis Software (Copenhagen
Trial Unit’s Trial Sequential Analysis Software,
hereafter: TSA Software, Copenhagen, Sweden).
Where original data were expressed as
continuous variables, meta-analyses were
performed using the mean difference (MD) or
standardized mean difference (SMD). SMD is
calculated using the formula: difference in
mean outcome between studies/standard
deviation (SD) of outcome among participants.
This method allows aggregation of outcomes
measured using different scales (opioid
consumption when combining different
opioid agents, times when combining hours
and minutes, score rating when using five-point
or ten-point scales, etc.). In all other cases,
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outcome incidence analysis was performed
using the risk ratios (RR). In order to include a
maximum number of appropriate studies and
avoid publication bias, incomplete data were
obtained by contacting the corresponding
author or estimation of the mean and the SD
on the basis of the sample size, median, and
range according to the method described by
Hozo and collaborators [14]. Where no
validated method was identified to convert
median and interquartile ranges to means and
SD, data were discarded. In articles where
outcomes were expressed as continuous
variables, a partial standardized mean ratio
was initially computed for each study, than
transformed into partial odds ratio (OR) using
Chinn’s formula [15]: LnOR = 1.814 9 SMD
(Ln: natural logarithm). The data were then
included as Ln(OR) and SD(LnOR) in the
software (Review Manager 5 software). Overall
SDM or RR (and 95% confidence intervals) were
then calculated using the inverse variance
method [8]. Regarding common cut-off values
for SMD, the Dex effect was considered small
when the SMD was greater than -0.4, moderate
when it was lying between -0.4 and -0.7, and
large when it was smaller than -0.7 [8].
Heterogeneity was assessed using I2 statistics.
This approach describes the percentage of the
variability in effect estimates (OR, MD, or SMD)
that is due to heterogeneity rather than
sampling error. According to the Cochrane
Review guidelines [8], the threshold for
heterogeneity is an I2[40% and a p\0.1 and
indicated the use of a random effect in OR and
SMD computation rather than a fixed-effects
model. The random-effects model assumes that
the observed effects are estimating different
intervention effects while a fixed-effects model
estimates the same ‘‘true’’ intervention effect.
Based on this principle, studies were weighted.
In the random-effects model, all studies are
equally weighted while in the fixed-effects
model, each study is weighted according to
the number of included patients. In addition,
because of the potential effect of some
confounding factors on results, subgroup
analyses for Dex effect were performed (when
at least two studies included the considered
outcome for the considered subgroup)
according to: the type of procedure, the mode
of administration (bolus alone, or infusion with
or without bolus), and the dose of bolus
administered (threshold for defining low and
high boluses was considered as the mean for
number of included studies[30 or the median
if the number of included studies\30). Finally,
overall results were also computed in studies
displaying low-risk bias for all checked items.
In order to confirm results of our
meta-analysis on the primary outcome, a
second set of analyses were performed using
the trial sequential method [16, 17]. This
statistical method allows combining effects of
studies and previous meta-analysis performed
on the same subject to correct results (the
adjustment of alpha-risk related to multiple
comparison in previous meta-analyses), predict
the possibility of a significant result in case of
low power of the actual analysis and estimates
the effect-size to be included in a meta-analysis
(termed the information size for meta-analysis)
to find a significant result. This analysis was
performed on the freeware Copenhagen Trial
Unit’s Trial Sequential Analysis Software,
hereafter: TSA Software, Copenhagen, Sweden.
In studies with more than one intervention
arm, in order to take into account all data, each
arm was considered as a study and compared to
the control group. However, given the weight
taken by those studies in overall results, a
sensitivity analysis was performed by removing
one arm and another in order to assess the effect
of these studies on outcome. Finally, to avoid
66 Pain Ther (2016) 5:63–80
calculation failure related to zero values in
RevMan and TSA, a 1 or 0.001 was added to all
groups when the number of events was equal to
0 in one group (for RevMan and TSA,
respectively).
Statistical methods are available to assess the
effects of unpublished studies on meta-analysis
results (publication bias). Publication bias is
assessed by studying the distribution of results
on a funnel plot, which is a scatter plot of the
intervention effect (RR, MD, or SMD) estimates
from individual studies against some measure of
each study’s size or precision (standard error of
the intervention effect). Funnel plot asymmetry
may indicate that some studies went
unpublished [18, 19]. This asymmetry can also
indicate result heterogeneity or poor
methodology in included studies [18, 19].
According to the Cochrane collaborative
guideline [8], it is suitable to assess publication
bias when analysis aggregates at least ten studies.
Results are expressed as RR, MD, or SMD
(95% confidence interval), I2, p value for I2
statistics.
RESULTS
Study Selection and Features
Using the above-described criteria, 545 pediatric
studies were found. Analysis allowed the
selection of 81 relevant randomized controlled
studies. Among these articles, 67 were discarded
for at least one of the following reasons: no pain
or analgesic data: 20, data not displayed: one,
data expressed as interquartile range (IQR): four
without a response from authors, not controlled
with placebo: four, association with other
compounds (ketamine): one, not administered
intraoperatively: 31, neurosurgery: one, cardiac
surgery: two, adult trials: two and abstract: one.
Characteristics of Included Studies
Analyses were carried out upon 14 articles
[20–33] (Table 1). There was no difference in
recorded information between assessors and no
second analysis was necessary. All studies were
performed during surgery (no anesthesia for
procedural sedation). Surgery performed
consisted of: adenotonsillectomy and
outpatient surgeries (Table 1). The selection
process is summarized in Fig. 1 and
characteristics of included studies are
displayed in Table 1. Three studies contained
three arms (two groups including patients
treated with Dex compared to one control
group): the study performed by Ghai and
collaborators [23] (both arms using a bolus of
Dex), the one performed by Meng and
collaborators [28] (both using a bolus mode)
and the study performed by Pestieau and
collaborator [30] (using either a bolus or a
continuous infusion). Postoperative pain
intensities were expressed as median (range) in
four studies [23, 24, 27, 32] and necessity
transformation to mean and SD. Finally, both
primary and secondary outcomes interested the
PACU period and no data in studies described
outcomes after this period.
Overall Results
Seven hundred and seventy patients received Dex
and 693 received placebo. Overall, the results
showed that intraoperative Dex administration
was significantly associated with an
opioid-sparing effect [RR = 0.31 (0.17, 0.59),
I2 = 76%, p\0.0001; Fig. 2a]. Sensitivity
analyses for this outcome including only one
arm of studies with more than on Dex group [23,
28] still found a Dex opioid-sparing effect
[RR = 0.31 (0.16, 0.61), I2 = 79%, p\0.0001 and
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RR = 0.29 (0.14, 0.57), I2 = 79%, p\0.0001,
interaction test: X2 = 0.03, df= 1, I2 = 0%,
p = 0.87]. Dex also displayed an improvement in
postoperative pain management [SMD = -1.18
(-1.88, -0.48), I2 = 91%, p\0.0001; Fig. 2b].
Sensitivity analyses including only one arm of
studies with more than one Dex group [23, 28, 30]
still displayed a significant reduction of pain in
Dex-treated patients [RR = 0.33 (0.14, 0.76),
I2 = 93%, p\0.0001 and RR = 0.29 (0.12, 0.66),
I2 = 93%, p\0.0001, interaction test: X2 = 0,
df= 1, I2 = 0%, p = 0.95]. PONV was carried on
three studies and found Dex ineffective in
decreasing their occurrence [RR = 0.67 (0.41,
1.08), I2 = 0%, p = 0.48; Fig. 2c].
Subgroup Analyses
Subgroup analyses were carried on the
following criteria: adenotonsillectomy versus
outpatient surgery, bolus administration of
Dex versus continuous administration and
low-dose bolus versus high-dose bolus. High
and low median bolus were chosen according
to the median value of boluses used in
studies (0.5 lg/kg), accordingly, low bolus
doses were \0.5 lg/kg and high bolus doses
were C0.5 lg/kg. Dex was still found to
decrease both postoperative opioid
consumption (Fig. 3a–c) and postoperative
pain intensity (Fig. 4a–c) except after
adenotonsillectomy and when boluses were
\0.5 lg/kg irrespective to the presence or
absence of a continuous administration
(Figs. 3a, 4a). However, subgroup analyses
interaction did not find a significant
difference between paired subgroups for all
outcomes (Figs. 3, 4).
Effect of Study’s Bias on Results
Including in the analysis studies with low-bias
risks, found Dex effective in decreasing opioid
consumption in PACU [three studies, RR = 0.44
(0.36, 0.54), I2 = 20%, p = 0.28] and
postoperative pain intensity [three studies,
SMD = -0.89 (-1.38, -0.41), I2 = 0%,
p = 0.43].
However, given the low number of studies of
low-bias included in this meta-analysis for
primary outcome, we performed a trial
sequential analysis (TSA) including studies
expressed as discrete data (nine studies on
overall 12 available [21–28, 31] for the primary
outcome because no inverse variance method is
available in the TSA software) and data of
low-bias risk studies to compute the relative
risk reduction in order to determine the number
of patients needed to found a significant result
[16, 17].
Results of TSA, confirmed the opioid-sparing
effect of Dex [RR = 0.49 (0.39, 0.62), I2 = 0%,
Screening Databases 
and Manual articles 
search : 545
Potential appropriate RCT : 81
RCT included in the meta analysis : 14
Unrelated studies : 339
Reviews : 48
Letters and case reports : 48
Cohort Studies : 29
No pain or analgesic data: 20
Data not displayed: 1
Data expressed as IQR: 4
Not controlled with placebo: 4
Association with other compounds: 1
Not administered intraoperatively: 31
Neurosurgery: 1
Cardiac surgery : 2
Adult trials: 2
Abstract : 1
Fig. 1 Meta-analysis ﬂowchart. IQR interquartile range,
RCT randomized controlled trial
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p = 0.44] and a cumulative z scores above the
significant threshold (Fig. 5). This analysis also
found the number of patients to be included in
this meta-analysis with an alpha risk of 5 % and
a power of 80 % to detect a relative risk
reduction of 34 % of 525 patients (Fig. 5a).
Finally, introducing a correction for previous
analysis [5], found Dex to continue exhibiting a
significant opioid-sparing effect (Fig. 5b). The
cumulative results of RevMan and TSA analyses
clearly indicate that the opioid-sparing effect of
Dex is valid assumption during pediatric
surgery.
Publication Bias Analyses
Concerning publication bias, according to
Cochrane recommendations (see Methods
section for publication bias), two outcomes
were examined, namely, opioid consumption
and postoperative pain and. Both funnel plots
(Fig. 6a and b, respectively) displayed an
asymmetry that might indicate either a great
heterogeneity in results or a publication bias
related to unpublished negative results.
DISCUSSION
The two main findings of the present study are
the following: Intraoperative administration of
Dex either as a bolus or a continuous
administration has a postoperative
opioid-sparing effect and improves the quality
of postoperative pain. The result of the primary
outcome was confirmed using the TSA with and
without correction for previous meta-analysis
on the same outcome. Despite the absence of a
significant difference between subgroups,
analyses according to the surgery performed,
the mode of Dex administration, and the dose
of the Dex bolus found that both
adenotonsillectomy and low bolus doses
(\0.5 lg/kg) impact Dex opioid-sparing effect
and postoperative pain quality. PONV
occurrence was not decreased by Dex, but this
outcome was supported by results of three
studies.
Results of the current meta-analysis were
similar to those found in the previous one
published in 2013 [5] concerning postoperative
pain management. However, the current
meta-analysis included more studies (overall
14 studies in comparison to the 11 included in
2013) and compared Dex to placebo. Moreover,
the primary outcome of our study was
computed on 12 studies in comparison to the
four used for the same outcome in the previous
meta-analysis [5]. This clearly confirms the
postoperative analgesic and opioid-sparing
effect of Dex. The observed postoperative
effect of Dex might involve its
pharmacokinetics properties: Dex has an
elimination half-life of approximately 2 h, and
as such may reduce pain intensity (and opioid
consumption) for some time after surgery,
especially in non-major surgeries such those
performed in the included studies (both in the
current meta-analysis and the previous one).
bFig. 2 a Forest plot of meta-analysis of the effects of Dex
versus placebo on opioid consumption in the PACU.
b Forest plot of meta-analysis of the effects of Dex versus
placebo on postoperative pain intensity in the PACU.
c Forest plot of meta-analysis of the effects of dexmedeto-
midine versus placebo on postoperative nausea and
vomiting in the PACU. The square in front of each study
(ﬁrst author and year of publication) is the RR for
individual trials, and the corresponding horizontal line is
the 95% CI. The lozenge at the bottom represents pooled
OR with 95% CI. Studies with more than one Dex arm are
displayed as author, name, year of publication_1, and
author name year of publication_2 (see Table 1 for exact
description of each arm). CI conﬁdence interval, Dex
dexmedetomidine, OR odds ratio, PACU postanesthesia
care unit, RR risk ratio, SE standard error, SMD
standardized mean difference
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Another interesting finding of this study is the
ineffective effect of Dex during
adenotonsillectomy. Dex did not exhibit the
opioid-sparing effect nor does it improve the
quality of postoperative pain management
during adenotonsillectomy. This might result
from the intense postoperative pain after this
procedure. This hypothesis is strongly suggested
by the absence of Dex effect on both opioid
consumption and postoperative pain during
this procedure. The second hypothesis is
derived from the subgroup analyses
concerning the bolus dose. Boluses\0.5 lg/kg,
either followed by a continuous administration
or not, were found ineffective in decreasing
both postoperative pain intensity and opioid
consumption. However, this hypothesis is
unlikely given that all studies performed
during adenotonsillectomy used boluses of
Dex C0.5 lg/kg. An alternative explanation for
this result is the amount of intraoperative
opioid administered intraoperatively with the
development of a subsequent hyperalgesia
[34–37]. This hypothesis is strongly supported
by the association of intraoperative and
postoperative opioid-sparing effect of Dex
observed in some studies included in this
meta-analysis: Patel’s studies [29] found no
intraoperative and postoperative
opioid-sparing effect of Dex. In contrast, using
the same anesthesia protocol, Soliman and
collaborators [33] found both an intraoperative
and a postoperative opioid-sparing effect of
Dex. Preventing opioid-induced hyperalgesia
might therefore represent an alternative
hypothesis explaining the postoperative
opioid-sparing effect of Dex found in our
meta-analysis and might represent an
interesting hypothesis to explore in future
studies. Finally, the absence of a postoperative
opioid-sparing effect of Dex during
adenotonsillectomy might also result from the
limited number of studies included to compute
this subgroup (four studies).
Interestingly, doses used in included studies
ranged from 0.3 to 2 lg/kg (median of 0.5 lg/
kg) and continuous administration during the
intraoperative period ranged from 0.2 to 0.7 lg/
kg/h (median of 0.2 lg/kg/h). These doses were
lower than those commonly used during
procedural sedation (especially during
pediatric imaging: bolus of 1 lg/kg and
continuous infusion of 0.5–2 lg/kg/h) [38].
This difference is logical given that during
painful procedures, Dex is used in
combination with other opioid and hypnotic
agents while imaging requires sedation that can
be achieved using Dex as the sole anesthetic
agent. Our results indicate that optimal bolus
dose of Dex to produce its analgesic and
opioid-sparing effects must be C0.5 lg/kg.
Although, this interesting finding had to be
further explored, this result gives an interesting
indication on the optimal dose of Dex to be
used to improve postoperative pain
management.
bFig. 3 Forest plot of subgroup analysis of the effect a of
the surgery, b of the bolus mode versus the bolus plus
continuous mode, and c the effect of a bolus of C0.5 lg/kg
versus a bolus\0.5 lg/kg, on Dex opioid-sparing effect in
the postanesthesia care unit. The square in front of each
study (ﬁrst author and year of publication) is the RR for
individual trials, and the corresponding horizontal line is
the 95% CI. The lozenge at the bottom represents pooled
OR with 95% CI. The test for subgroup difference
represents the interaction test between groups. Studies
with more than one Dex arm are displayed as author name,
year of publication_1, and author name, year of publica-
tion_2 (see Table 1 for exact description of each arm). CI
conﬁdence interval, Dex dexmedetomidine, RR risk ratio,
SE standard error
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Despite the reduction of opioids
consumption, Dex did not affect the incidence
PONV in our meta-analysis. However, this
probably reflects the heterogeneity of results
and the small number of studies focusing on
this outcome (three studies) [4, 39]. This
explanation is highly supported by the finding
in the recent meta-analysis on the same topic in
adults that included more studies.
The results presented in this meta-analysis
are of a great interest for management of
postoperative rehabilitation in pediatric
patients. Every effort if made today in order to
decrease postoperative opioid administration
[40]. This allows a rapid switch from the
intravenous administration of those
compounds (often administered via a patient-
or nurse-controlled analgesia) to an oral
administration of non-opioid analgesics [40,
41]. This accelerates the discharge from the
hospital while most surgical care can be
performed at home. In addition, decreasing
the amount of morphine has been shown to
decrease opioid-related side effects such nausea,
vomiting, and constipation; and decrease the
time of first oral intake, even after abdominal
surgery. Altogether, results of this meta-analysis
strongly encourage studies on the effects of Dex
on rapid postoperative rehabilitation.
Limitations of the Study
This meta-analysis suffers many limitations. The
primary outcome of the current meta-analysis
(postoperative opioid consumption) was the
primary outcome of only two individual trials
(Table 1). As a consequence, most data were
computed with secondary outcomes of
individual studies. However, using the trial
sequence analysis allow to confirm our results
and the adequate patients included in this
meta-analysis. Data from studies designed with
more than one active group were analyzed with
each arm considered as a separate study.
Although this would increase the weight of the
considered study in the analysis, this allowed
avoiding publication bias.
Subgroup analyses were performed with the
aim of reducing heterogeneity and to identify
factors influencing results. However, this goal
was not achieved for most outcomes. This
probably explains the absence of statistical
difference between subgroups (interaction test)
even when showing different results on
outcomes. Consequently, our results must be
interpreted cautiously, especially for outcomes
involving lesser numbers of analyzed studies.
Using funnel plots, we demonstrated suspected
publication bias for two outcomes—pain
intensity in PACU and postoperative opioid
consumption in PACU—indicating that some
studies of these outcomes with negative results
were not published. Alternatively, this funnel
plot asymmetry might also result from the great
heterogeneity between studies.
The current meta-analysis was designed to
examine the postoperative effects of Dex versus
placebo during pediatric surgery. As such, no
bFig. 4 Forest plot of subgroup analysis of a the surgery,
b the bolus mode versus the bolus plus continuous mode,
and c the effect of a bolus of DexC0.5 lg/kg versus a bolus
\0.5 lg/kg, on Dex effect on postoperative pain intensity
in the postanesthesia care unit. The square in front of each
study (ﬁrst author and year of publication) is the SMD for
individual trials, and the corresponding horizontal line is
the 95% CI. The lozenge at the bottom represents pooled
OR with 95% CI. The test for subgroup difference
represents the interaction test between groups. Studies
with more than one Dex arm are displayed as author name,
year of publication_1, and author name year of publica-
tion_2 (see Table 1 for exact description of each arm). CI
conﬁdence interval, Dex dexmedetomidine SE standard
error, SMD standardized mean difference
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conclusions can be made about the efficacy of
Dex in comparison to other sedative or
analgesic agents such as morphine. Our study
is also limited regarding the effects of Dex on
intraoperative hemodynamics. This outcome
was excluded from our meta-analysis for the
following reasons: heterogeneity in numerical
expression of this outcome, heterogeneity in
types of surgery and Dex infusion regimes,
which could all result in hemodynamic
disturbances, and the absence of an exhaustive
search for articles displaying this outcome.
Finally, due to the design of the included
studies, no data for postoperative analgesia are
available after discharge from the PACU. This
represents the most challenging point for future
studies.
CONCLUSIONS
Our meta-analysis shows that intraoperative
Dex, when compared to placebo, is associated
with reduced in postoperative opioid
consumption and an improvement of pain
management during PACU stay. More studies
are necessary to assess the dose-effect of Dex on
postoperative pain management and its
benefice during longer postoperative period in
order to precise its advantages during rapid
postoperative rehabilitation programs.
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bFig. 5 a Trial sequential analysis graph (x-axis studies
effect, y-axis cumulative z scores). The displaying in the full
line displays the cumulative z score, the horizontal dotted
line the boundaries of signiﬁcance (results in the region
within these boundaries are non-signiﬁcant), the vertical
line the meta-analysis information size (size of patients to
be included in order to show a signiﬁcant outcome: 525).
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of the z score outside the futility region and crossing the
monitoring boundary curve (constructed with low-risk bias
studies), the opioid-sparing effect of dexmedetomidine is
conﬁrmed. b Correction for previous meta-analyses of trial
sequential analysis graph: (x-axis studies effect, y-axis
cumulative z scores). The upper curve represents the actual
z scores analysis without correction and the lower one the
corrected z scores taking in account previous analyses
Fig. 6 a Funnel plot of Dex effect upon opioid consump-
tion in PACU. b Funnel plot of Dex effect upon
postoperative pain intensity in PACU. Graphs display
the intervention effect (RR or SMD) estimates from
individual studies in the x-axis against some measure of
each study’s size or precision (standard error of the
intervention effect) in the y-axis. Dex dexmedetomidine,
PACU postanesthesia care unit, RR risk ratio, SE standard
error, SMD standardized mean difference
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